药品行政保护品种介绍生物医学技术药物

[]100727669(2004)0320174202:(,200040)[]2003211205[]2003212203[](1944-),,,,,[]Phn:862212621023970Fax:[phone]E2mail:[e-mail][];;;;;;B[]D923.42;R979.5;R977[]CB:B():(,PedvaxHIB):1993816:(Merckco.,Inc,):AUS93081617:BUS94021805:1994218:7.5a,2001818:4695624:B(,PRP)B11(OMPC)PRPOMPCPRP,B:,0.5mL,:15gbPRP;250gOMPC,225g();120000,2.0mg,:,214mo,2mo1(0.5mL),2mo2(0.5mL)15mo,B,(0.5mL):,:(octreotide):(Sandostatin)11Fig1Structureofoctreotide:1993323:(SandozAG):ACH93032302:BCH93092302:1993923:7.5a,2001323:677449:,0.05,0.1,0.5,1mgmL-1:Sandostatin:,,,:;;;:(1),0.20.3mg,812h0.050.1mg;(2),0.05mg,12,,0.10.2mg,3;(3),0.1mg,3,,0.25mg(4),0.1mg,3,7d:Productbriefofadministrativeprotec2tionofpharmaceuticals:biomedicaltechnologydrugsWANGWei(TheScientificandTechnicalInformationInstituteofShanghaiMunicipalDrugAdministration,SHANGHAI200040,China)471(ChinJNewDrugsClinRem),20043,233E2mail:[e-mail][KEYWORDS]patents;biomedicaltechnology;biopharmaceutics;vaccines;octreotide;administra2tiveprotectionofpharmaceuticals;vaccines,com2bined,hemophilustypeB[]100727669(2004)0320175202(,255200)[]2003204218[]2003205208[](1963-),,,,,[]Phn:862533242522553E2mail:[e-mail][];;[][]R44;R576[]B,,,,,,[1],,()()(),,,,,CT(ERCP),MR(MRCP),(EUS),CA1929[2]KUBO[3]51,10mm,40mm,10mm,86%,40%,,B,ERCPMRCPCT2[4]10%,,,,,,B;,ERCP;CT[3],,,,,,,BCT[4],,1/3;571(ChinJNewDrugsClinRem),20043,233E2mail:[e-mail]